

PERSONAL INFORMATION

Markus Peck-Radosavljevic

WORK EXPERIENCE

-
- January 2016- Present **Chair, Internal Medicine & Gastroenterology with Centralized Emergency Service**
KABEG, Klinikum Klagenfurt am Wörthersee (Austria)
Management of a large Department of Internal Medicine with the Subdisciplines Gastroenterology, Hepatology, Endocrinology, Rheumatology and Nephrology including the Centralized Emergency Service. This involves organizing the clinical service, the postgraduate medical training and the clinical research unit in the third-largest hospital in Austria.
- December 1992-December 2015 **Vice Chair, Department of Gastroenterology**
Medical University of Vienna (Austria)
Starting with trainee in 1992, I became board certified physician there in 1997, moved on to become Associate Professor of Medicine in 1999 and was appointed Vice Chair of the Department in 2005.
- December 1991-December 1992 **Internship**
Landeskrankenanstaltengesellschaft OÖ (Austria)
Basic medical training in psychiatry (5 months), general surgery (6 months) and urology (1 month)
- December 1990-December 1991 **Research Associate**
Baylor College of Medicine Houston (United States)
Participation in the Postprandial Lipemia Study, a substudy of the ARIC Study (Atherosclerosis Risk in Communities), Molecular studies in the regulation of the Apo AI/CIII/AIV gene Clusters in the rat liver
- April 2011-April 2013 **Vice Secretary, European Association for the Study of the Liver (EASL)**
EASL, 7 Rue Daubin Geneva (Switzerland)
Second in charge of the European Association for the Study of the Liver: main responsibilities were EU policy tasks, coordination of Hepamap (the roadmap publication liver disease research in Europe) and organizing the International liver Congress.
- April 2013-April 2015 **Secretary General, European Association for the Study of the Liver (EASL)**
EASL, 7 Rue Daubin Geneva (Switzerland)
Chief Executive of the European Association of the Liver, responsible for all operations, including international policy and communications, organizing the International Liver Congress, EU policy tasks, interaction with WHO and a number of professional medical associations, clinical practice guidelines development

EDUCATION AND TRAINING

-
- 1983-March 1990 **Doctor of Medicine**
Medical School at Karl-Franzens-Universität Graz (Austria)
- December 1992-December 1997 **Board certification for internal medicine**
Medical University of Vienna, Training in Internal Medicine (ÖÄK-Arztnummer: 35545-84) (Austria)
Clinical training in internal medicine, finished with the certification of the Austrian Doctor's Chamber.
- February 2001-February 2003 **Certification for Gastroenterology & Hepatology (Zusatzfacharzt)**
Medical University of Vienna (Austria)
- February 2004-February 2006 **Certification of Intensive Care Medicine (Zusatzfacharzt)**
Medical University of Vienna (Austria)

| | |
|---------------------------|--|
| -January 2011 | Certification for Infectious Diseases (Zusatzfacharzt) Medical University of Vienna (Austria) |
| September 2000-April 2001 | Postgraduate Course for Leadership in Medicine University of Salzburg (Austria) |
| April 2004-October 2005 | Master of Science "Health Care Management" Donau-Universität Krems Master program Health Care Management (Austria) |
| December 2006- | MBA Health Care Management University of Economics, Vienna (Austria) |

ADDITIONAL INFORMATION

Expertise

Publications (1-246)

- Schwabl P, Hambruch E, Budas GR, Supper P, Burnet M, Liles JT, Birkel M, et al. The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. *Biomedicines* 2021;9.
- Razpotnik M, Bota S, Kutilek M, Essler G, Weber-Eibel J, Maieron A, Peck-Radosavljevic M. The bleeding risk after endoscopic ultrasound-guided puncture of pancreatic masses. *Scand J Gastroenterol* 2021;56:205-210.
- Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. *Gut* 2021;70:204-214.
- Turco L, Villanueva C, La Mura V, Garcia-Pagan JC, Reiberger T, Genesca J, Groszmann RJ, et al. Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. *Clin Gastroenterol Hepatol* 2020;18:313-327 e316.
- Scheiner B, Stattermayer AF, Schwabl P, Bucsecs T, Paternostro R, Bauer D, Simbrunner B, et al. Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. *Liver Int* 2020;40:393-404.
- Reiberger T, Schwabl P, Trauner M, Peck-Radosavljevic M, Mandorfer M. Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. *J Vis Exp* 2020.
- Razpotnik M, Bota S, Wimmer P, Hackl M, Lesnik G, Alber H, Peck-Radosavljevic M. The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria. *Liver Int* 2020.
- Razpotnik M, Bota S, Essler G, Weber-Eibel J, Peck-Radosavljevic M. Endoscopic ultrasound (EUS) in pancreatic masses with inconclusive radiologic workup - a case series and short review of the literature. *Med Ultrason* 2020.
- Pfisterer N, Schmidbauer C, Riedl F, Maieron A, Stadlbauer V, Hennlich B, Schwarzer R, et al. Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. *Wien Klin Wochenschr* 2020.
- Peck-Radosavljevic M, Danese S, Hartmann D, Saftoiu A, Van Hooetegem P, Committee UEGPA. COVID-19 and digestive health. *United European Gastroenterol J* 2020;8:624-626.
- Peck-Radosavljevic M. Digestive health in Europe - lack of concerted action, exposed by COVID-19, starts with lack of uniform data reporting in liver disease. *Infect Dis (Lond)* 2020;52:828-829.
- Mandorfer M, Peck-Radosavljevic M, Ferenci P, Reiberger T. Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient. *Liver Int* 2020;40:988-989.
- Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stattermayer AF, Pinter M, et al. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. *Hepatology* 2020;71:1023-1036.
- Hatzakis A, Lazarus JV, Cholongitas E, Baptista-Leite R, Boucher C, Busoi CS, Deuffic-Burban S, et al. Securing sustainable funding for viral hepatitis elimination plans. *Liver Int* 2020;40:260-270.
- Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, et al. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. *Hepatology* 2020;72:198-212.

16. Eder M, Darmann E, Haller MC, Bojic M, Peck-Radosavljevic M, Huditz R, Bond G, et al. Markers of potassium homeostasis in salt losing tubulopathies- associations with hyperaldosteronism and hypomagnesemia. *BMC Nephrol* 2020;21:256.
17. Bureau C, Adebayo D, Chalret de Rieu M, Elkrief L, Valla D, Peck-Radosavljevic M, McCune A, et al. Corrigendum to 'Alfapump(R) system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study' [J Hepatol 67 (2017) 940-949]. *J Hepatol* 2020;72:595-596.
18. Stift J, Semmler G, Walzel C, Mandorfer M, Schwarzer R, Schwabl P, Paternostro R, et al. Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. *Dig Liver Dis* 2019;51:1144-1151.
19. Scheiner B, Ulbrich G, Mandorfer M, Reiberger T, Muller C, Waneck F, Trauner M, et al. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. *United European Gastroenterol J* 2019;7:850-858.
20. Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. *Aliment Pharmacol Ther* 2019;49:1323-1333.
21. Scheiner B, Kirstein M, Popp S, Hucke F, Bota S, Rohr-Udilova N, Reiberger T, et al. Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. *Liver Cancer* 2019;8:203-217.
22. Ricke J, Klumpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, Gasbarrini A, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. *J Hepatol* 2019;71:1164-1174.
23. Peck-Radosavljevic M, Singal AK. DAAs prevent HCC - the plot thickens. *Dig Liver Dis* 2019;51:460-461.
24. Peck-Radosavljevic M, Simon K, Iacobellis A, Hassanein T, Kayali Z, Tran A, Makara M, et al. Luspatorbopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). *Hepatology* 2019;70:1336-1348.
25. Paternostro R, Heinisch BB, Reiberger T, Mandorfer M, Bardach C, Lampichler K, Seeland B, et al. Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. *Hepatol Res* 2019;49:201-211.
26. Newland A, Bentley R, Jakubowska A, Liebman H, Lorens J, Peck-Radosavljevic M, Taieb V, et al. A systematic literature review on the use of platelet transfusions in patients with thrombocytopenia. *Hematology* 2019;24:679-719.
27. Mandorfer M, Peck-Radosavljevic M, Ferenci P, Reiberger T. Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient. *Liver Int* 2019.
28. Haider C, Hnat J, Wagner R, Huber H, Timelthaler G, Grubinger M, Coulouarn C, et al. Transforming Growth Factor-beta and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma. *Hepatology* 2019;69:222-236.
29. Chromy D, Mandorfer M, Bucsics T, Schwabl P, Scheiner B, Schmidbauer C, Christopher Aichelburg M, et al. High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. *United European Gastroenterol J* 2019;7:507-516.
30. Stepanova M, Nader F, Bureau C, Adebayo D, Elkrief L, Valla D, Peck-Radosavljevic M, et al. Patients with refractory ascites treated with alfapump(R) system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. *Qual Life Res* 2018.
31. Schwarzer R, Kivaranovic D, Paternostro R, Mandorfer M, Reiberger T, Trauner M, Peck-Radosavljevic M, et al. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. *Aliment Pharmacol Ther* 2018.
32. Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B, Reiberger T, et al. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. *Aliment Pharmacol Ther* 2018;47:86-94.
33. Rohr-Udilova N, Bauer E, Timelthaler G, Eferl R, Stolze K, Pinter M, Seif M, et al. Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma. *Oncotarget* 2018;9:10054-10068.
34. Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. *Lancet Oncol* 2018;19:682-693.

35. Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. *Aliment Pharmacol Ther* 2018.
36. Pfisterer N, Dexheimer C, Fuchs EM, Bucsics T, Schwabl P, Mandorfer M, Gessl I, et al. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. *Aliment Pharmacol Ther* 2018.
37. Paternostro R, Heinisch BB, Reiberger T, Mandorfer M, Schwarzer R, Seeland B, Trauner M, et al. Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. *Liver Int* 2018.
38. Paternostro R, Heinisch BB, Reiberger T, Mandorfer M, Bardach C, Lampichler K, Seeland B, et al. Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. *Hepato Res* 2018.
39. Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, et al. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. *J Viral Hepat* 2018;25 Suppl 1:6-17.
40. Palmer DH, Ma YT, Peck-Radosavljevic M, Ross P, Graham J, Fartoux L, Deptala A, et al. A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. *Br J Cancer* 2018.
41. Nakov R, Peck-Radosavljevic M. Young gastrointestinal angle: How to prepare and submit a job application. *United European Gastroenterol J* 2018;6:160-161.
42. Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, Ay C, et al. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. *Aliment Pharmacol Ther* 2018.
43. Mandorfer M, Scheiner B, Stattermayer AF, Schwabl P, Paternostro R, Bauer D, Schaefer B, et al. Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. *Aliment Pharmacol Ther* 2018.
44. Mandorfer M, Reiberger T, Peck-Radosavljevic M. Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response. *Gastroenterology* 2018;154:1550-1551.
45. Mandorfer M, Bucsics T, Hutya V, Schmid-Scherzer K, Schaefer B, Zoller H, Ferlitsch A, et al. Liver disease in adults with 1-antitrypsin deficiency. *United European Gastroenterology Journal* 2018;6:710-718.
46. Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, et al. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. *Gut* 2018;67:380-388.
47. Chromy D, Schwabl P, Bucsics T, Scheiner B, Strassl R, Mayer F, Aichelburg MC, et al. Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. *Wien Klin Wochenschr* 2018;130:105-114.
48. Bureau C, Adebayo D, de Rieu MC, Elkrief L, Valla D, Peck-Radosavljevic M, McCune A, et al. Corrigendum to "Alfapump(R) system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study" [*J Hepatol* 67 (2017) 940-949]. *J Hepatol* 2018;68:630.
49. Bucsics T, Schoder M, Diermayr M, Feldner-Busztin M, Goeschl N, Bauer D, Schwabl P, et al. Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience. *PLoS One* 2018;13:e0189414.
50. Yoshida EM, Kwo P, Agarwal K, Duvoux C, Durand F, Peck-Radosavljevic M, Lilly L, et al. Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. *Ann Hepatol* 2017;16:375-381.
51. Wengert GJ, Baltzer PAT, Bickel H, Thurner P, Breitenseher J, Lazar M, Pones M, et al. Differentiation of Intrahepatic Cholangiocellular Carcinoma from Hepatocellular Carcinoma in the Cirrhotic Liver Using Contrast-enhanced MR Imaging. *Acad Radiol* 2017.
52. Vitale A, Peck-Radosavljevic M, Giannini EG, Vibert E, Sieghart W, Van Poucke S, Pawlik TM. Personalized treatment of patients with very early hepatocellular carcinoma. *J Hepatol* 2017;66:412-423.
53. Strauss R, Rose T, Flint SM, Klotsche J, Haupl T, Peck-Radosavljevic M, Yoshida T, et al. Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options. *J Mol Med (Berl)* 2017.
54. Steiner S, Bucsics T, Schwabl P, Mandorfer M, Scheiner B, Aichelburg MC, Grabmeier-Pfistershammer K, et al. Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. *Wien Klin Wochenschr* 2017.

55. Schwabl P, Mandorfer M, Steiner S, Scheiner B, Chromy D, Herac M, Bucsics T, et al.

Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. *Aliment Pharmacol Ther* 2017;45:139-149.

56. Schwabl P, Hambruch E, Seeland BA, Hayden H, Wagner M, Garnys L, Strobel B, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. *J Hepatol* 2017;66:724-733.
57. Scheiner B, Parada-Rodriguez D, Bucsics T, Schwabl P, Mandorfer M, Pfisterer N, Riedl F, et al. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. *Scand J Gastroenterol* 2017;52:1008-1015.
58. Rockstroh JK, Ingiliz P, Petersen J, Peck-Radosavljevic M, Welzel TM, Van der Valk M, Zhao Y, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease. *Antivir Ther* 2017;22:225-236.
59. Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, et al. Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. *World J Gastroenterol* 2017;23:2448-2452.
60. Reiberger T, Puspok A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, et al. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). *Wien Klin Wochenschr* 2017;129:135-158.
61. Pinter M, Haupt L, Hucke F, Bota S, Bucsics T, Trauner M, Peck-Radosavljevic M, et al. The impact of thyroid hormones on patients with hepatocellular carcinoma. *PLoS One* 2017;12:e0181878.
62. Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. *Liver Int* 2017;37:778-793.
63. Paternostro R, Wagner D, Reiberger T, Mandorfer M, Schwarzer R, Ferlitsch M, Trauner M, et al. Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. *Wien Klin Wochenschr* 2017;129:8-15.
64. Paternostro R, Reiberger T, Mandorfer M, Schwarzer R, Schwabl P, Bota S, Ferlitsch M, et al. Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. *J Gastroenterol Hepatol* 2017;32:184-190.
65. Mandorfer M, Schwabl P, Peck-Radosavljevic M, Reiberger T, Vienna HIV, Liver Study G, the Vienna Hepatic Hemodynamic L. Letter: sustained virological response and liver healing - authors' reply. *Aliment Pharmacol Ther* 2017;45:1173-1174.
66. Louvet A, Peck-Radosavljevic M. Evidence for a role of genetics in alcoholic hepatitis: Data from the STOPAH randomized controlled trial. *J Hepatol* 2017;67:12-14.
67. Li S, Peck-Radosavljevic M, Ubl P, Wadsak W, Mitterhauser M, Rainer E, Pinter M, et al. The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. *Eur J Nucl Med Mol Imaging* 2017;44:1732-1741.
68. Herzer K, Welzel TM, Spengler U, Hinrichsen H, Klinker H, Berg T, Ferenci P, et al. Real-world experience with daclatasvir plus sofosbuvir +/- ribavirin for post-liver transplant HCV recurrence and severe liver disease. *Transpl Int* 2017;30:243-255.
69. De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B, Magenta L, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. *Liver Int* 2017;37:694-699.
70. Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R, Yun C, et al. Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial. *Ann Intern Med* 2017;166:109-117.
71. Chromy D, Schwabl P, Bucsics T, Scheiner B, Strassl R, Mayer F, Aichelburg MC, et al. Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. *Wien Klin Wochenschr* 2017.
72. Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo B-Y, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. *European Journal of Cancer* 2017;81:17-25.
73. Busk TM, Moller S, Pedersen EB, Gerbes A, Krag A, Peck-Radosavljevic M, Frankova S, et al. Aquaporin-2 excretion in hospitalized patients with cirrhosis: Relation to development of renal insufficiency and mortality. *J Gastroenterol Hepatol* 2017;32:1087-1093.
74. Bureau C, Adebayo D, Chalret de Rieu M, Elkrief L, Valla D, Peck-Radosavljevic M, McCune A, et al. Alfapump(R) system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. *J Hepatol* 2017;67:940-949.

75. Bucsics T, Schoder M, Goeschl N, Schwabl P, Mandorfer M, Diermayr M, Feldner M, et al.

- Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. *Digestive and Liver Disease* 2017;49:1360-1367.
76. Asenbaum U, Ba-Ssalamah A, Mandorfer M, Nolz R, Furtner J, Reiberger T, Ferlitsch A, et al. Effects of Portal Hypertension on Gadoteric Acid-Enhanced Liver Magnetic Resonance: Diagnostic and Prognostic Implications. *Invest Radiol* 2017;52:462-469.
77. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. *Gut* 2016;65:1861-1870.
78. Scheiner B, Schwabl P, Steiner S, Bucsics T, Chromy D, Aichelburg MC, Grabmeier-Pfistershammer K, et al. Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study. *Medicine (Baltimore)* 2016;95:e4061.
79. Rutter K, Etschmaier A, Ferlitsch M, Maieron A, Hametner S, Horvatits T, Paternostro R, et al. von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. *Dig Liver Dis* 2016;48:1194-1199.
80. Rockstroh JK, Ingiliz P, Petersen J, Peck-Radosavljevic M, Welzel TM, Van der Valk M, Zhao Y, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease. *Antivir Ther* 2016.
81. Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. *ESMO Open* 2016;1:e000042.
82. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. *Lancet Infect Dis* 2016;16:685-697.
83. Mandorfer M, Steiner S, Schwabl P, Payer BA, Aichelburg MC, Grabmeier-Pfistershammer K, Trauner M, et al. Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. *Wien Klin Wochenschr* 2016;128:414-420.
84. Mandorfer M, Schwabl P, Steiner S, Scheiner B, Chromy D, Bucsics T, Stattermayer AF, et al. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/HCV-coinfected patients with advanced liver disease. *AIDS* 2016.
85. Mandorfer M, Schwabl P, Steiner S, Reiberger T, Peck-Radosavljevic M. Advances in the management of HIV/HCV coinfection. *Hepatol Int* 2016.
86. Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, Chromy D, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. *Journal of Hepatology* 2016;65:692-699.
87. Mandorfer M, Kozbial K, Peck-Radosavljevic M, Ferenci P. Letter: can persisting liver stiffness indicate increased risk for HCC, after successful anti-HCV therapy? - authors' reply. *Aliment Pharmacol Ther* 2016;43:544-545.
88. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, Stättermayer AF, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. *Journal of Hepatology* 2016;65:856-858.
89. Koeberle D, Dufour JF, Demeter G, Li Q, Ribi K, Samaras P, Saletti P, et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): A randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). *Ann Oncol* 2016.
90. Ikeda M, Shimizu S, Sato T, Morimoto M, Kojima Y, Inaba Y, Hagihara A, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. *Ann Oncol* 2016;27:2090-2096.
91. Gyori GP, Schwarzer R, Puspok A, Schoff R, Silberhumer GR, Langer FB, Trauner M, et al. Endoscopic versus surgical management of biliary complications - Outcome analysis after 1188 orthotopic liver transplantations. *Dig Liver Dis* 2016.
92. Graziadei I, Zoller H, Fickert P, Schneeberger S, Finkenstedt A, Peck-Radosavljevic M, Müller H, et al. Indications for liver transplantation in adults. *Wiener klinische Wochenschrift* 2016;128:679-690.
93. De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B, Magenta L, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. *Liver Int* 2016.

94. Bucsics T, Schwabl P, Mandorfer M, Peck-Radosavljevic M. Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP). *J Hepatol* 2016.
95. Bucsics T, Schwabl P, Mandorfer M, Bota S, Sieghart W, Ferlitsch A, Trauner M, et al. The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. *Liver Int* 2016;36:1649-1656.
96. Trebicka J, Wix C, von Heydebrand M, Hittatiya K, Reiberger T, Klein S, Schierwagen R, et al. Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension. *Liver Int* 2015;35:1393-1402.
97. Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: Modalities, indication, and patient selection. *J Hepatol* 2015;62:1187-1195.
98. Schwabl P, Bucsics T, Soucek K, Mandorfer M, Bota S, Blacky A, Hirschl AM, et al. Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. *Liver Int* 2015.
99. Schwabl P, Bota S, Salzl P, Mandorfer M, Payer BA, Ferlitsch A, Stift J, et al. New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. *Liver Int* 2015;35:381-390.
100. Ricke J, Bulla K, Kolligs F, Peck-Radosavljevic M, Reimer P, Sangro B, Schott E, et al. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. *Liver Int* 2015;35:620-626.
101. Reichl P, Dengler M, van Zijl F, Huber H, Fuhrlinger G, Reichel C, Sieghart W, et al. Axl activates autocrine transforming growth factor-beta signaling in hepatocellular carcinoma. *Hepatology* 2015;61:930-941.
102. Pinter M, Ulbrich G, Sieghart W, Kölblinger C, Reiberger T, Li S, Ferlitsch A, et al. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. *Radiology* 2015;0:142140.
103. Peck-Radosavljevic M, Angeli P, Cordoba J, Farges O, Valla D. Managing complications in cirrhotic patients. *United European Gastroenterol J* 2015;3:80-94.
104. Peck-Radosavljevic M. 30years of the Journal of Hepatology - The flagship journal and the crown-jewel of EASL. *J Hepatol* 2015;62:S4-5.
105. Peck-Radosavljevic M. Editorial: dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma. *Aliment Pharmacol Ther* 2015;41:1216-1217.
106. Peck-Radosavljevic M. 50 years of EASL--from a European to a global perspective. *J Hepatol* 2015;62:4-5.
107. Mandorfer M, Steiner S, Schwabl P, Payer BA, Aichelburg MC, Lang G, Grabmeier-Pfistershammer K, et al. Response-Guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study. *J Infect Dis* 2015;211:729-735.
108. Mandorfer M, Payer BA, Schwabl P, Steiner S, Ferlitsch A, Aichelburg MC, Stattermayer AF, et al. Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. *Liver Int* 2015;35:876-885.
109. Mandorfer M, Kozbial K, Freissmuth C, Schwabl P, Stattermayer AF, Reiberger T, Beinhardt S, et al. Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. *Alimentary Pharmacology & Therapeutics* 2015:n/a-n/a.
110. Jansen C, Reiberger T, Huang J, Eischeid H, Schierwagen R, Mandorfer M, Anadol E, et al. Circulating MiRNA-122 Levels Are Associated with Hepatic Necroinflammation and Portal Hypertension in HIV/HCV Coinfection. *PLoS One* 2015;10:e0116768.
111. Giannini EG, Peck-Radosavljevic M. Platelet Dysfunction: Status of Thrombopoietin in Thrombocytopenia Associated with Chronic Liver Failure. *Semin Thromb Hemost* 2015.
112. Ferlitsch A, Bota S, Paternostro R, Reiberger T, Mandorfer M, Heinisch B, Salzl P, et al. Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient. *Liver Int* 2015.
113. Bucsics T, Mandorfer M, Schwabl P, Bota S, Sieghart W, Ferlitsch A, Trauner M, et al. Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: a retrospective cohort study. *J Gastroenterol Hepatol* 2015.
114. Bota S, Paternostro R, Etschmaier A, Schwarzer R, Salzl P, Mandorfer M, Kienbacher C, et al. Performance of 2-D Shear Wave Elastography in Liver Fibrosis Assessment Compared with Serologic Tests and Transient Elastography in Clinical Routine. *Ultrasound Med Biol* 2015.

115. Beinhardt S, Peck-Radosavljevic M, Hofer H, Ferenci P. Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting. *Transpl Int* 2015.
116. Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The evolve-1 randomized clinical trial. *JAMA* 2014;312:57-67.
117. Strassl R, Reiberger T, Honsig C, Payer BA, Mandorfer M, Grabmeier-Pfistershammer K, Rieger A, et al. Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients. *J Viral Hepat* 2014;21:508-516.
118. Sirlin CB, Hussain HK, Jonas E, Kanematsu M, Min Lee J, Merkle EM, Peck-Radosavljevic M, et al. Consensus report from the 6th International forum for liver MRI using gadoxetic acid. *J Magn Reson Imaging* 2014;40:516-529.
119. Schwabl P, Payer BA, Grahovac J, Klein S, Horvatits T, Mitterhauser M, Stift J, et al. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. *J Hepatol* 2014;60:1135-1142.
120. Salzl P, Reiberger T, Ferlitsch M, Payer BA, Schwengerer B, Trauner M, Peck-Radosavljevic M, et al. Evaluation of Portal Hypertension and Varices by Acoustic Radiation Force Impulse Imaging of the Liver Compared to Transient Elastography and AST to Platelet Ratio Index. *Ultraschall Med* 2014.
121. Ricke J, Bulla K, Kolligs F, Peck-Radosavljevic M, Reimer P, Sangro B, Schott E, et al. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. *Liver Int* 2014.
122. Reichl P, Dengler M, van Zijl F, Huber H, Fuhrlinger G, Reichel C, Sieghart W, et al. Signaling of Axl via 14-3-3zeta activates autocrine transforming growth factor-beta signaling in hepatocellular carcinoma. *Hepatology* 2014.
123. Purevsambuu T, Bota S, Hucke F, Hofer H, Ferenci P, Sieghart W, Peck-Radosavljevic M. Hepatocellular Carcinoma (HCC) incidence in chronic hepatitis C (CHC) according to sustained virologic response (SVR) and baseline characteristics. *J Hepatol* 2014;60 (Suppl. 1):A52.
124. Pinter M, Hucke F, Zielonke N, Waldhor T, Trauner M, Peck-Radosavljevic M, Sieghart W. Incidence and mortality trends for biliary tract cancers in Austria. *Liver Int* 2014;34:1102-1108.
125. Pinter M, Hucke F, Zielonke N, Trauner M, Sieghart W, Peck-Radosavljevic M. Epidemiological Trends of Hepatocellular Carcinoma in Austria. *Digestive Diseases* 2014;32:664-669.
126. Peck-Radosavljevic M, Sieghart W, Hucke F. Reply. *Hepatology* 2014;59:2425-2426.
127. Peck-Radosavljevic M. Drug therapy for advanced-stage liver cancer. *Liver Cancer* 2014;3:125-131.
128. Peck-Radosavljevic M. Go East. *J Hepatol* 2014;60:4-5.
129. Nolz R, Asenbaum U, Schoder M, Wibmer A, Einspieler H, Prusa AM, Peck-Radosavljevic M, et al. Diagnostic workup of primary sclerosing cholangitis: The benefit of adding gadoxetic acid-enhanced T1-weighted magnetic resonance cholangiography to conventional T2-weighted magnetic resonance cholangiography. *Clin Radiol* 2014;69:499-508.
130. Mandorfer M, Reiberger T, Payer BA, Breitenecker F, Aichelburg MC, Obermayer-Pietsch B, Rieger A, et al. Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels. *J Viral Hepat* 2014;21:33-41.
131. Mandorfer M, Peck-Radosavljevic M, Reiberger T. Reply. *Gastroenterology* 2014;147:942.
132. Mandorfer M, Payer BA, Schwabl P, Steiner S, Ferlitsch A, Aichelburg MC, Stattermayer AF, et al. Revisiting liver disease progression in HIV/HCV-coinfected patients: The influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. *Liver Int* 2014.
133. Mandorfer M, Payer BA, Scheiner B, Breitenecker F, Aichelburg MC, Grabmeier-Pfistershammer K, Rieger A, et al. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. *Liver Int* 2014;34:69-77.
134. Mandorfer M, Payer BA, Niederecker A, Lang G, Aichelburg MC, Strassl R, Boesecke C, et al. Therapeutic Potential of and Treatment with Boceprevir/Telaprevir-Based Triple-Therapy in HIV/Chronic Hepatitis C Co-Infected Patients in a Real-World Setting. *AIDS Patient Care STDS* 2014;28:221-227.
135. Mandorfer M, Bota S, Schwabl P, Bucsecs T, Pfisterer N, Summereder C, Hagmann M, et al. Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites. *PLoS One* 2014;9:e110503.

136. Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, Hagmann M, et al.

- Non-selective beta Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. *Gastroenterology* 2014;146:1680-1690 e1681.
137. Maieron A, Salzl P, Peck-Radosavljevic M, Trauner M, Hametner S, Schofl R, Ferenci P, et al. Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. *Aliment Pharmacol Ther* 2014;39:331-338.
138. Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L, Wculek SK, et al. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. *Nat Cell Biol* 2014;16:972-981.
139. Jansen C, Leeming DJ, Mandorfer M, Byrjalsen I, Schierwagen R, Schwabl P, Karsdal MA, et al. PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension. *PLoS One* 2014;9:e108544.
140. Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel W, Muller C, Heinzl H, et al. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. *J Hepatol* 2014;60:118-126.
141. Hucke F, Sieghart W, Peck-Radosavljevic M. Reply to the Letters to the Editor regarding the sequential ART-Score. *J Hepatol* 2014;61:177-178.
142. Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Muller C, Heinzl H, et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. *J Hepatol* 2014;61:1287-1296.
143. Colombo M, Peck-Radosavljevic M. Entering a new era in the treatment of hepatitis C. *Dig Liver Dis* 2014;46S5:S157.
144. Bota S, Peck-Radosavljevic M. Non-invasive evaluation of patients with viral hepatitis. *Minerva Gastroenterol Dietol* 2014;60:39-54.
145. Balassy C, Feier D, Peck-Radosavljevic M, Wrba F, Witoszynskij S, Kiefer B, Reiter G, et al. Susceptibility-weighted MR imaging in the grading of liver fibrosis: a feasibility study. *Radiology* 2014;270:149-158.
146. Sieghart W, Pinter M, Hucke F, Graziadei I, Schoniger-Hekele M, Muller C, Vogel W, et al. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. *Hepatology* 2013;57:2224-2234.
147. Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Muller C, Heinzl H, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. *Hepatology* 2013;57:2261-2273.
148. Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, Heinisch BB, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. *Gut* 2013;62:1634-1641.
149. Reiberger T, Payer BA, Schwabl P, Hayden H, Horvath T, Jager B, Hummel T, et al. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. *Liver Int* 2013;33:561-568.
150. Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, Lammert F, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. *J Hepatol* 2013;58:911-921.
151. Peck-Radosavljevic M, Sieghart W, Hucke F. Reply to kudo et al.: "ART score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma". *Hepatology* 2013.
152. Peck-Radosavljevic M, Angermayr B, Datz C, Ferlitsch A, Ferlitsch M, Fuhrmann V, Hafner M, et al. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). *Wien Klin Wochenschr* 2013;125:200-219.
153. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, et al. Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. *Gastroenterology* 2013;144:1426-U1189.
154. Mandorfer M, Reiberger T, Payer BA, Peck-Radosavljevic M. The Influence of Portal Pressure on the Discordance Between Absolute CD4+ Cell Count and CD4+ Cell Percentage in HIV/Hepatitis C Virus-Coinfected Patients. *Clin Infect Dis* 2013;56:904-905.
155. Mandorfer M, Reiberger T, Payer BA, Ferlitsch A, Breitenacker F, Aichelburg MC, Obermayer-Pietsch B, et al. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfecting patients. *AIDS* 2013;27:227-232.
156. Mandorfer M, Neukam K, Reiberger T, Payer BA, Rivero A, Puoti M, Boesecke C, et al. The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfecting patients. *AIDS* 2013;27:2707-2714.

157. Keane C, O'Shea D, Reiberger T, Peck-Radosavljevic M, Farrell G, Bergin C, Gardiner CM.

Variation in Both IL28B and KIR2DS3 Genes Influence Pegylated Interferon and Ribavirin Hepatitis C Treatment Outcome in HIV-1 Co-Infection. *PLoS One* 2013;8:e66831.

158. Ferlitsch M, Peck-Radosavljevic M, Ferlitsch A. Reply. *Hepatology* 2013;58:1189-1190.
159. Bota S, Sporea I, Peck-Radosavljevic M, Sirli R, Tanaka H, Iijima H, Saito H, et al. The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: A retrospective multicentre study. *Dig Liver Dis* 2013.
160. Bota S, Herkner H, Sporea I, Salzi P, Sirli R, Neghina AM, Peck-Radosavljevic M. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. *Liver Int* 2013;33:1138-1147.
161. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. *J Hepatol* 2013;58:593-608.
162. Sporea I, Bota S, Peck-Radosavljevic M, Sirli R, Tanaka H, Iijima H, Badea R, et al. Acoustic Radiation Force Impulse elastography for fibrosis evaluation in patients with chronic hepatitis C: an international multicenter study. *Eur J Radiol* 2012;81:4112-4118.
163. Sieghart W, Pinter M, Reisinger M, Muller C, Ba-Ssalamah A, Lammer J, Peck-Radosavljevic M. Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. *Eur Radiol* 2012;22:1214-1223.
164. Sieghart W, Pinter M, Dauser B, Rohr-Udilova N, Piguat AC, Prager G, Hayden H, et al. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. *J Hepatol* 2012;57:592-599.
165. Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, et al. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. *Z Gastroenterol* 2012;50:57-72.
166. Rohr-Udilova N, Sieghart W, Eferl R, Stoiber D, Björkhem-Bergman L, Eriksson LC, Stolze K, et al. Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma. *Hepatology* 2012;55:1112-1121.
167. Reiberger T, Peck-Radosavljevic M. The "pegylated" story continues - Perhaps because both ends (alpha2a and alpha2b) are true? *J Hepatol* 2012;57:226-228.
168. Reiberger T, Payer BA, Ferlitsch A, Sieghart W, Breitenecker F, Aichelburg MC, Schmied B, et al. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. *Antivir Ther* 2012;17:1327-1334.
169. Reiberger T, Ferlitsch A, Payer BA, Pinter M, Schwabl P, Stift J, Trauner M, et al. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography-a large single center experience. *Wien Klin Wochenschr* 2012;124:395-402.
170. Reiberger T, Ferlitsch A, Payer BA, Pinter M, Homoncik M, Peck-Radosavljevic M. Non-selective beta-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. *J Gastroenterol* 2012;47:561-568.
171. Procopet B, Bureau C, Peron JM. Letter: sorafenib in portal hypertension. *Aliment Pharmacol Ther* 2012;36:994; author reply 994-995.
172. Pinter M, Sieghart W, Reiberger T, Rohr-Udilova N, Ferlitsch A, Peck-Radosavljevic M. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study. *Aliment Pharmacol Ther* 2012;35:83-91.
173. Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Konigsberg R, Stauber R, et al. Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib. *Radiology* 2012;263:590-599.
174. Peck-Radosavljevic M, Stauber RE. BCLC - now also an internationally acclaimed prognostic system? *Liver Int* 2012;32:1037-1038.
175. Peck-Radosavljevic M, Sieghart W, Kolblinger C, Reiter M, Schindl M, Ulbrich G, Steininger R, et al. Austrian Joint OGGH-OGIR-OGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. *Wien Klin Wochenschr* 2012;124:104-110.
176. Peck-Radosavljevic M. Back to basics: staging and prognosis in HCC for medical oncologist. *J Hepatol* 2012;56:488-489.
177. Payer BA, Reiberger T, Breitenecker F, Aichelburg MC, Schuster C, Heil PM, Scherzer TM, et al. The risk of infections in HIV-HCV coinfected patients during antiviral therapy with pegIFN+RBV. *J Infect* 2012;65:142-149.
178. Payer BA, Reiberger T, Aberle J, Ferenci P, Holzmann H, Rieger A, Peck-Radosavljevic M. IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. *Eur J Clin Invest* 2012;42:599-606.

179. Kosi L, Reiberger T, Payer BA, Grabmeier-Pfistershammer K, Strassl R, Rieger A, Peck-Radosavljevic M. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. *J Viral Hepat* 2012;19:801-810.
180. Jaroszewicz J, Reiberger T, Meyer-Olson D, Mauss S, Vogel M, Ingiliz P, Payer BA, et al. Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection. *PLoS One* 2012;7:e43143.
181. Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, Payer BA, et al. Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. *Hepatology* 2012;56:1439-1447.
182. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. *Nat Rev Gastroenterol Hepatol* 2011;8:212-223.
183. Sieghart W, Wang X, Schmid K, Pinter M, Konig F, Bodingbauer M, Wrba F, et al. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. *J Hepatol* 2011;54:89-97.
184. Sahora K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, Teleky B, et al. NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. *Surgery* 2011;149:311-320.
185. Reiberger T, Rutter K, Ferlitsch A, Payer BA, Hofer H, Beinhardt S, Kundi M, et al. Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients With Hepatitis C Virus Infection. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 2011;9:602-608.e601.
186. Reiberger T, Payer BA, Kosi L, Heil PM, Rieger A, Peck-Radosavljevic M. Concomitant Highly Active Antiretroviral Therapy Leads to Smaller Decline and Faster Recovery of CD4+ Cell Counts During and After Pegylated Interferon Plus Ribavirin Therapy in HIV-Hepatitis C Virus Coinfected Patients. *J Infect Dis* 2011;203:1802-1806.
187. Reiberger T, Obermeier M, Payer BA, Baumgarten A, Weitner L, Moll A, Christensen S, et al. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. *Antivir Ther* 2011;16:815-824.
188. Pinter M, Sieghart W, Reisegger M, Wrba F, Peck-Radosavljevic M. Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report. *Wien Klin Wochenschr* 2011;123:61-64.
189. Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. *Alimentary Pharmacology & Therapeutics* 2011;34:949-959.
190. PeckRadosavljevic M. Reply. *Clinical Gastroenterology and Hepatology* 2011;9:1005.
191. Peck-Radosavljevic M, Pinter M, Sieghart W. Hepatocellular carcinoma treated with sorafenib: authors reply. *Alimentary Pharmacology & Therapeutics* 2011;34:1348-1349.
192. Peck-Radosavljevic M, Boletis J, Besisik F, Ferraz ML, Alric L, Samuel D, Messinger D, et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. *Clin Gastroenterol Hepatol* 2011;9:242-248.
193. Peck-Radosavljevic M. Imaging and early diagnosis of hepatocellular carcinoma. *Minerva Gastroenterol Dietol* 2011;57:273-286.
194. Hucke F, Sieghart W, Schoniger-Hekele M, Peck-Radosavljevic M, Muller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? *Wien Klin Wochenschr* 2011;123:542-551.
195. Zulehner G, Mikula M, Schneller D, van Zijl F, Huber H, Sieghart W, Grasl-Kraupp B, et al. Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. *Am J Pathol* 2010;176:472-481.
196. Ulbrich G, Pinter M, Reiberger T, Ferlitsch A, Sieghart W, Peck-Radosavljevic M. Interim safety-analysis of the AVATACE-1 trial: Bevacizumab as inhibitor of collateral tumor vessel-growth during transarterial chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC). A double-blind randomized placebo-controlled pilot-trial. *J Hepatol* 2010;52:A121.
197. Ulbrich G, Kölblinger C, Pinter M, Reiberger T, Ferlitsch A, Sieghart W, Lammer J, et al. AVATACE-1 trial: Bevacizumab as inhibitor of collateral tumor-vessel-growth during transarterial chemoembolisation (TACE) for Hepatocellular Carcinoma - a double-blind, randomized, placebo-controlled pilot-trial. *Hepatology* 2010;52:A1763.
198. Schmid M, Peck-Radosavljevic M, Konig F, Mittermaier C, Gangl A, Ferenci P. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in

patients with cirrhosis. *Liver Int* 2010;30:574-582.

199. Sarrazin C, Berg T, Ross RS, Schirmacher P, Wedemeyer H, Neumann U, Schmidt HH, et al. [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. *Z Gastroenterol* 2010;48:289-351.
200. Reiberger T, Kosi L, Maresch J, Breitenecker F, Payer BA, Wrba F, Rieger A, et al. Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. *J Infect Dis* 2010;202:156-160.
201. Reiberger T, Ferlitsch A, Sieghart W, Kreil A, Breitenecker F, Rieger A, Schmied B, et al. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. *J Viral Hepat* 2010;17:400-409.
202. Pramhas S, Homoncik M, Ferenci P, Ferlitsch A, Scherzer T, Gangl A, Peck-Radosavljevic M. von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4. *Antivir Ther* 2010;15:831-839.
203. Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A, Bolondi L. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. *Eur J Gastroenterol Hepatol* 2010;22:391-398.
204. Peck-Radosavljevic M, Deutsch J, Ferenci P, Graziadei I, Hofer H, Holzmann H, Huber WD, et al. [4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009]. *Wien Klin Wochenschr* 2010;122:280-302.
205. Peck-Radosavljevic M. Hepatocellular carcinoma: the place of new medical therapies. *Therap Adv Gastroenterol* 2010;3:259-267.
206. Peck-Radosavljevic M. TACE it or leave it: hard choices for intermediate-stage hepatocellular carcinoma patients beyond perfect health. *Liver Int* 2010;30:3-4.
207. Payer BA, Reiberger T, Rutter K, Beinhardt S, Staettermayer AF, Peck-Radosavljevic M, Ferenci P. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfecting patient. *J Clin Virol* 2010.
208. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W, et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. *Cancer Cell* 2010;17:286-297.
209. Sieghart W, Fellner S, Reiberger T, Ulbrich G, Ferlitsch A, Wacheck V, Peck-Radosavljevic M. Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma. *Dig Liver Dis* 2009.
210. Schoniger-Hekele M, Kettenbach J, Peck-Radosavljevic M, Muller C. Octreotide treatment of patients with hepatocellular carcinoma - a retrospective single centre controlled study. *J Exp Clin Cancer Res* 2009;28:142.
211. Schmid M, Mittermaier C, Voller B, Fialka-Moser V, Gangl A, Peck-Radosavljevic M. Postural control in patients with liver cirrhosis: a posturographic study. *Eur J Gastroenterol Hepatol* 2009;21:915-922.
212. Reiberger T, Angermayr B, Schwabl P, Rohr-Udilova N, Mitterhauser M, Gangl A, Peck-Radosavljevic M. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. *J Hepatol* 2009;51:865.
213. Rautou PE, Angermayr B, Garcia-Pagan JC, Moucari R, Peck-Radosavljevic M, Raffa S, Bernuau J, et al. Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes. *J Hepatol* 2009;51:47-54.
214. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Konigsberg R, Weissmann A, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. *Oncologist* 2009;14:70-76.
215. Jalili A, Kinaciyani T, Barisani T, Peck-Radosavljevic M, Stingl G, Geusau A, Wohrl S. Successful treatment of refractory Behcet's disease with the TNF-alpha blocker infliximab. *Iran J Immunol* 2009;6:55-58.
216. Ferlitsch A, Schmid M, Schmidinger H, Homoncik M, Pleiner-Duxneuner J, Ulbrich G, Gangl A, et al. Atropine for prevention of cardiac dysrhythmias in patients with hepatocellular carcinoma undergoing percutaneous ethanol instillation: a randomized, placebo-controlled, double-blind trial. *Liver Int* 2009;29:715-720.
217. Angermayr B, Luca A, Konig F, Bertolini G, Ploner M, Gridelli B, Ulbrich G, et al. Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of End-stage Liver Disease score. *Eur J Clin Invest* 2009;39:65-71.

218. Reiberger T, Rasoul-Rockenschaub S, Rieger A, Ferenci P, Gangl A, Peck-Radosavljevic M.

- Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection. *Eur J Clin Invest* 2008;38:421-429.
219. Reiberger T, Aberle JH, Kundi M, Kohrgruber N, Rieger A, Gangl A, Holzmann H, et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. *Antivir Ther* 2008;13:969-976.
220. Pinter M, Wichlas M, Schmid K, Plank C, Muller C, Wrba F, Peck-Radosavljevic M. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. *Eur J Gastroenterol Hepatol* 2008;20:1012-1019.
221. Muller C, Schoniger-Hekele M, Scherthaner R, Renner B, Peck-Radosavljevic M, Brichta A, Wrba F, et al. Percutaneous ethanol instillation therapy for hepatocellular carcinoma - a randomized controlled trial. *Wien Klin Wochenschr* 2008;120:608-618.
222. Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F, Wang X, et al. Mammalian Target of Rapamycin Pathway Activity in Hepatocellular Carcinomas of Patients Undergoing Liver Transplantation. *Transplantation* 2007;83:425-432.
223. Schmid K, Wang X, Haitel A, Sieghart W, Peck-Radosavljevic M, Bodingbauer M, Rasoul-Rockenschaub S, et al. KiSS-1 overexpression as an independent prognostic marker in hepatocellular carcinoma: an immunohistochemical study. *Virchows Arch* 2007;450:143-149.
224. Luca A, Angermayr B, Bertolini G, Koenig F, Vizzini G, Ploner M, Peck-Radosavljevic M, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. *Liver Transpl* 2007;13:1174-1180.
225. Ferlitsch A, Teml A, Reinisch W, Ulbrich G, Wrba F, Homoncik M, Gangl A, et al. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. *Am J Gastroenterol* 2007;102:2495-2503.
226. Ferlitsch A, Steindl-Munda P, Haefner M, Peck-Radosavljevic M, Madl C, Potzi R, Homoncik M, et al. Prescintigraphic morphine application for abdominal adenocarcinoma imaging, with technetium-99m methoxy isobutyl isonitrile. *Hell J Nucl Med* 2007;10:14-18.
227. Dempfle CE, Gulba D, Kirchmaier CM, Klamroth R, Korte W, Lorenz R, Peck-Radosavljevic M, et al. [Clinical assessment of potential fields of application of recombinant factor VIIa in internal and pediatric diseases. Recommendations of an expert group.]. *Med Klin (Munich)* 2007;102:70-81.
228. Bodingbauer M, Wekerle T, Pakrah B, Roschger P, Peck-Radosavljevic M, Silberhumer G, Grampp S, et al. Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation. *Am J Transplant* 2007;7:1763-1769.
229. Blum M, Mueller C, Peck-Radosavljevic M, Wrba F, Berlakovich G, Muhlbacher F, Steiniger R, et al. MR-guided percutaneous ethanol ablation of hepatocellular carcinomas before liver transplantation. *Minim Invasive Ther Allied Technol* 2007;16:230-240.
230. Silberhumer GR, Hetz H, Rasoul-Rockenschaub S, Peck-Radosavljevic M, Soliman T, Steiniger R, Muehlbacher F, et al. Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival? *Transpl Int* 2006;19:275-281.
231. Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S, Bodingbauer M, et al. Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy. *J Hepatol* 2006;44:151-157.
232. Sieghart W, Homoncik M, Jilma B, Formann E, Ferenci P, Gangl A, Peck-Radosavljevic M. Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis C. *Thromb Haemost* 2006;95:260-266.
233. Pieber K, Crevenna R, Nuhr MJ, Quittan M, Peck-Radosavljevic M, Fialka-Moser V, Wiesinger GF. Aerobic capacity, muscle strength and health-related quality of life before and after orthotopic liver transplantation: preliminary data of an Austrian transplantation centre. *J Rehabil Med* 2006;38:322-328.
234. Peck-Radosavljevic M. Portal hypertension--old problem, new therapeutic solutions. *Wien Med Wochenschr* 2006;156:397-403.
235. Panzer S, Seel E, Brunner M, Kormoczi GF, Schmid M, Ferenci P, Peck-Radosavljevic M. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. *Eur J Haematol* 2006;77:513-517.
236. Li S, Beheshti M, Peck-Radosavljevic M, Oezer S, Grumbeck E, Schmid M, Hamilton G, et al. Comparison of (11)C-acetate positron emission tomography and (67)Gallium citrate scintigraphy in patients with hepatocellular carcinoma. *Liver Int* 2006;26:920-927.
237. Kormoczi GF, Saemann MD, Buchta C, Peck-Radosavljevic M, Mayr WR, Schwartz DW, Dunkler D, et al. Influence of clinical factors on the haemolysis marker haptoglobin. *Eur J Clin Invest* 2006;36:202-209.

238. Homoncik M, Sieghart W, Formann E, Schmid M, Ferenci P, Gangl A, Jilma B, et al. Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy. *Am J Gastroenterol* 2006;101:2275-2282.
239. Giannini EG, Zaman A, Kreil A, Floreani A, Dulbecco P, Testa E, Sohaey R, et al. Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study. *Am J Gastroenterol* 2006;101:2511-2519.
240. Weidekamm C, Cejna M, Kramer L, Peck-Radosavljevic M, Bader TR. Effects of TIPS on liver perfusion measured by dynamic CT. *AJR Am J Roentgenol* 2005;184:505-510.
241. Schmid M, Kreil A, Jessner W, Homoncik M, Datz C, Gangl A, Ferenci P, et al. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon {alpha} mono and combination therapy regimens. *Gut* 2005;54:1014-1020.
242. Rand T, Loewe C, Schoder M, Schmook MT, Peck-Radosavljevic M, Kettenbach J, Wolf F, et al. Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate. *Cardiovasc Intervent Radiol* 2005;28:313-318.
243. Peck-Radosavljevic M, Trauner M, Schreiber F. Austrian consensus on the definition and treatment of portal hypertension and its complications. *Endoscopy* 2005;37:667-673.
244. Homoncik M, Ferlitsch A, Ferenci P, Formann E, Jilma B, Gangl A, Panzer S, et al. Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. *Aliment Pharmacol Ther* 2005;21:49-55.
245. Funk GC, Doberer D, Osterreicher C, Peck-Radosavljevic M, Schmid M, Schneeweiss B. Equilibrium of acidifying and alkalinizing metabolic acid-base disorders in cirrhosis. *Liver Int* 2005;25:505-512.
246. Ferlitsch A, Pleiner J, Mittermayer F, Schaller G, Homoncik M, Peck-Radosavljevic M, Wolzt M. Vasoconstrictor hyporeactivity can be reversed by antioxidants in patients with advanced alcoholic cirrhosis of the liver and ascites. *Crit Care Med* 2005;33:2028-2033.
247. Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Havlik E, Schima W, Traub-Weidinger T, et al. Iodine-123-vascular endothelial growth factor-165 ((123)I)-VEGF(165)). Biodistribution, safety and radiation dosimetry in patients with pancre-atic carcinoma. *Q J Nucl Med Mol Imaging* 2004;48:198-206.
248. Homoncik M, Jilma-Stohlavetz P, Schmid M, Ferlitsch A, Peck-Radosavljevic M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. *Aliment Pharmacol Ther* 2004;20:437-443.
249. Ferlitsch A, Kreil A, Bauer E, Schmidinger H, Schillinger M, Gangl A, Peck-Radosavljevic M. Bradycardia and sinus arrest during percutaneous ethanol injection therapy for hepatocellular carcinoma. *Eur J Clin Invest* 2004;34:218-223.
250. Berlakovich GA, Soliman T, Freundorfer E, Windhager T, Bodingbauer M, Wamser P, Hetz H, et al. Pretransplant screening of sobriety with carbohydrate-deficient transferrin in patients suffering from alcoholic cirrhosis. *Transpl Int* 2004;17:617-621.
251. Angermayr B, Cejna M, Peck-Radosavljevic M. Management von Patienten vor und nach Implantation eines transjugulären intrahepatischen portosystemischen Shunts (TIPS) -Bericht der Vienna TIPS Study Group. *J Gastroenterol Hepatol Erkr* 2004;1:11-14.
252. Angermayr B, Cejna M, Karnel F, Gschwantler M, Konig F, Pidlich J, Mendel H, et al. Transjugular intrahepatic portosystemic shunt in Vienna--a decade later. *Wien Klin Wochenschr* 2004;116:608-613.
253. Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Hamilton G, Kurtaran A, Pirich C, et al. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. *Ann Oncol* 2003;14:1274-1277.
254. Cauza E, Peck-Radosavljevic M, Ulrich-Pur H, Datz C, Gschwantler M, Schoniger-Hekele M, Hackl F, et al. Mutations of the HFE gene in patients with hepatocellular carcinoma. *Am J Gastroenterol* 2003;98:442-447.
255. Angermayr B, Cejna M, Koenig F, Karnel F, Hackl F, Gangl A, Peck-Radosavljevic M. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. *Hepatology* 2003;38:1043-1050.
256. Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, Mendel H, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. *Gut* 2003;52:879-885.

257. Wichlas M, Weidekamm C, Kreil A, Pidlich J, Gangl A, Peck-Radosavljevic M. Antagonisation

- of the antiproliferative action of IFN-alpha on megakaryocytic cell lines by thrombopoietin (TPO) [Abstract]. *J Hepatol* 2002;36:A256.
258. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, Gangl A, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. *Gastroenterology* 2002;123:141-151.
259. Peck-Radosavljevic M, Hofmann H, Ferenci P, Rasoul-Rockenschaub S. Sensitivity to IFN-a in patients with recurrent hepatitis C scheduled for combination therapy after orthotopic liver transplantation [Abstract]. *Hepatology* 2002;36 (Pt. 2):A63.
260. Hofer H, Bankl HC, Wrba F, Steindl-Munda P, Peck-Radosavljevic M, Osterreicher C, Mueller C, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. *Am J Gastroenterol* 2002;97:2880-2885.
261. Cejna M, Peck-Radosavljevic M, Thurnher S, Schoder M, Rand T, Angermayr B, Lammer J. ePTFE-Covered Stent-Grafts for Revision of Obstructed Transjugular Intrahepatic Portosystemic Shunt. *Cardiovasc Intervent Radiol* 2002;25:365-372.
262. Cejna M, Peck-Radosavljevic M, Schoder M, Thurnher S, Ba-Ssalamah A, Angermayr B, Kaserer K, et al. Repeat interventions for maintenance of transjugular intrahepatic portosystemic shunt function in patients with Budd-Chiari syndrome. *J Vasc Interv Radiol* 2002;13:193-199.
263. Angermayr B, Cejna M, Schoder M, Wrba F, Valent P, Gangl A, Peck-Radosavljevic M. Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. *Blood* 2002;99:4246-4247.
264. Wiesinger GF, Quittan M, Zimmermann K, Nuhr M, Wichlas M, Bodingbauer M, Asari R, et al. Physical performance and health-related quality of life in men on a liver transplantation waiting list. *J Rehabil Med* 2001;33:260-265.
265. Wichlas M, Kollars M, Weidekamm C, Kreil A, Gangl A, Geissler K, Peck-Radosavljevic M. "Thrombopoietin (TPO) antagonizes the antiproliferative action of IFN-a on human bone marrow [Abstract]. *J Hepatol* 2001;34:A 585.
266. Peck-Radosavljevic M, Ferenci P, Graziadei I, Vogel W, Rockenschaub S, Riely C, Voigt M, et al. Pegyliertes (40 kDa) IFN-a2a (Pegasys) bei Hepatitis C Rezidiv nach OLT: präliminärer Bericht [Abstract]. *Z. Gastroenterol.* 2001;39:885.
267. Peck-Radosavljevic M. Hypersplenism. *Eur J Gastroenterol Hepatol* 2001;13:317-323.
268. Li S, Peck-Radosavljevic M, Koller E, Koller F, Kaserer K, Kreil A, Kapiotis S, et al. Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: Possible implication for tumour scintigraphy. *Int J Cancer* 2001;91:789-796.
269. Cejna M, Peck-Radosavljevic M, Thurnher SA, Hittmair K, Schoder M, Lammer J. Creation of transjugular intrahepatic portosystemic shunts with stent-grafts: initial experiences with a polytetrafluoroethylene-covered nitinol endoprosthesis. *Radiology* 2001;221:437-446.
270. Peck-Radosavljevic M, Wichlas M, Zacherl J, Stiegler G, Stohlawetz P, Fuchsjäger M, Kreil A, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. *Blood* 2000;95:795-801.
271. Peck-Radosavljevic M, Pidlich J. Der transjuguläre intrahepatische portosystemische Shunt (TIPS). *Wien Klin Wochenschr* 2000;112:947-954.
272. Peck-Radosavljevic M. Thrombocytopenia in liver disease. *Can J Gastroenterol* 2000;14 Suppl D:60D-66D.
273. Kreil A, Wenisch C, Brittenham G, Looareesuwan S, Peck-Radosavljevic M. Thrombopoietin in *Plasmodium falciparum* malaria. *Br J Haematol* 2000;109:534-536.
274. Zedtwitz-Liebenstein K, Podesser B, Peck-Radosavljevic M, Graninger W. Intestinal tuberculosis presenting as fever of unknown origin in a heart transplant patient. *Infection* 1999;27:289-290.
275. Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, Peck-Radosavljevic M, et al. DOTA-Ianreotide: a novel somatostatin analog for tumor diagnosis and therapy. *Endocrinology* 1999;140:5136-5148.
276. Peck-Radosavljevic M, Zacherl J, Wichlas M, Sims P, Meng YG, Panzer S, Lipinski E, et al. Thrombopoietic cytokines and reversal of thrombocytopenia after liver transplantation. *Eur J Gastroenterol Hepatol* 1999;11:151-156.
277. Peck-Radosavljevic M, Puspok A, Potzi R, Oberhuber G. Histological findings after routine biopsy at the gastro-oesophageal junction. *Eur J Gastroenterol Hepatol* 1999;11:1265-1270.
278. Peck-Radosavljevic M, Prokesch R, Schmid K, Frossard M, Wichlas M, Gendo A, Gangl A, et al. Fulminant lethal tuberculous pneumonia (Sepsis tuberculosis gravissima) with ARDS in a non-immunocompromised western European middle-aged man. *Wien Klin Wochenschr*

1999;111:157-160.

279. Oberhuber G, Puspok A, Peck-Radosavljevic M, Kutilek M, Lamprecht A, Chott A, Vogelsang H, et al. Aberrant esophageal HLA-DR expression in a high percentage of patients with Crohn's disease. *Am J Surg Pathol* 1999;23:970-976.
280. Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, Pangerl T, et al. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, ^{99m}Tc-P829. *Cancer Res* 1998;58:1850-1859.
281. Virgolini I, Kurtaran A, Leimer M, Kaserer K, Peck-Radosavljevic M, Angelberger P, Hubsch P, et al. Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. *J Nucl Med* 1998;39:1575-1579.
282. Stiegler G, Stohlawetz P, Peck-Radosavljevic M, Jilma B, Pidlich J, Wichlas M, Hocker P, et al. Direct evidence for an increase in thrombopoiesis after liver transplantation. *Eur J Clin Invest* 1998;28:755-759.
283. Pidlich J, Peck-Radosavljevic M, Wildling R, Lipinski E, Hartter E, Lenz K, Müller C, et al. Atrial natriuretic factor after transjugular intrahepatic portosystemic shunt in liver cirrhosis and ascites. *Acta Chir. Austriaca* 1998;30:189-195.
284. Pidlich J, Peck-Radosavljevic M, Kranz A, Wildling R, Winkelbauer FW, Lammer J, Mayer C, et al. Transjugular intrahepatic portosystemic shunt and cardiac arrhythmias. *J Clin Gastroenterol* 1998;26:39-43.
285. Peck-Radosavljevic M, Wichlas M, Pidlich J, Sims P, Meng G, Zacherl J, Garg S, et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. *Hepatology* 1998;28:1424-1429.
286. Peck-Radosavljevic M, Pidlich J, Bergmann M, Ferenci P, Seelos C, Wichlas M, Lipinski E, et al. Preoperative TNM-classification is a better prognostic indicator for recurrence of hepatocellular carcinoma after liver transplantation than albumin mRNA in peripheral blood. *Liver Transplant Oncology Group. J Hepatol* 1998;28:497-503.
287. Virgolini I, Pangerl T, Bischof C, Smith-Jones P, Peck-Radosavljevic M. Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer? *Eur J Clin Invest* 1997;27:645-647.
288. Pidlich J, Cichini GM, Reinisch W, Peck-Radosavljevic M, Renner F. Angiotensin-converting enzyme inhibition in cirrhotic patients--pharmacokinetics of ramipril. *Acta Med Austriaca* 1997;24:15-18.
289. Peck-Radosavljevic M, Zacherl J, Meng YG, Pidlich J, Lipinski E, Langle F, Steininger R, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? *J Hepatol* 1997;27:127-131.
290. Muller C, Pfeffel F, Peck-Radosavljevic M, Petermann D, Oesterreicher C, Pidlich J. Prevalence of hepatitis G virus in patients with hepatocellular carcinoma. *J Viral Hepat* 1997;4:411-414.
291. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Yang Q, Radosavljevic M, Leimer M, et al. ¹²³I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. *Nucl Med Biol* 1996;23:685-692.
292. Virgolini I, Angelberger P, Li S, Yang Q, Kurtaran A, Raderer M, Neuhold N, et al. In vitro and in vivo studies of three radiolabelled somatostatin analogues: ¹²³I-octreotide (OCT), ¹²³I-Tyr-3-OCT and ¹¹¹In-DTPA-D-Phe-1-OCT. *Eur J Nucl Med* 1996;23:1388-1399.
293. Lucas A, Yue W, Jiang XY, Liu L, Yan W, Bauer J, Schneider W, et al. Development of an avian model for restenosis. *Atherosclerosis* 1996;119:17-41.
294. Radosavljevic M, Temsch E, Hammer J, Pfeffel F, Mayer G, Renner F, Pidlich J, et al. Elevated levels of serum carbohydrate deficient transferrin are not specific for alcohol abuse in patients with liver disease. *J Hepatol* 1995;23:706-711.
295. Lin-Lee YC, Strobl W, Soyal S, Radosavljevic M, Song M, Gotto AM, Jr., Patsch W. Role of thyroid hormone in the expression of apolipoprotein A-IV and C-III genes in rat liver. *J Lipid Res* 1993;34:249-259.
296. Radosavljevic M, Lin-Lee YC, Soyal SM, Strobl W, Seelos C, Gotto AM, Jr., Patsch W. Effect of sucrose diet on expression of apolipoprotein genes A-I, C-III and A-IV in rat liver. *Atherosclerosis* 1992;95:147-156.
297. Lucas A, Radosavljevic MJ, Lu E, Gaffney EJ. Characterization of human coronary artery atherosclerotic plaque fluorescence emission. *Can J Cardiol* 1990;6:219-228.

298. Nimpf J, Radosavljevic MJ, Schneider WJ. Oocytes from the mutant restricted ovulator hen lack

receptor for very low density lipoprotein. J Biol Chem 1989;264:1393-1398.
 299. Nimpf J, Radosavljevic M, Schneider WJ. Specific postendocytic proteolysis of apolipoprotein B in oocytes does not abolish receptor recognition. Proc Natl Acad Sci U S A 1989;86:906-910.

Annex B: Reviewer for Scientific Journals
 Alimentary Pharmacology & Therapeutics,
 European Journal of Gastroenterology and Hepatology,
 European Journal of Clinical Investigation,
 Gastroenterology,
 Gut,
 Hepatology,
 Journal of Hepatology,
 Journal of Gastroenterology and Hepatology,
 Liver International
 Lancet,
 Nephrology Dialysis Transplantation,
 Transplant International,
 Wiener klinische Wochenschrift,
 World Journal of Gastroenterology

- Projects**
- III NASH Intercept REGENERATE - Treatment of NASH Patients with Liver Fibrosis PI Jun. 2016-ongoing
 - III Active Mb Crohn Efficacy and safety of IMP in subject with active crohn´s disease PI Dec 2016
 - NIS Steatohepatitis Exploratory study for predictive markers PI Since 2016 ongoing
 - NIS PCSK9-Inhibitor Observational Serial Chart in Subjects with Hyperlipidaemia PI Since 2017-ongoing
 - NIS HCC Genetic Risk Factors for Alcoholic Liver Cirrhosis PI
 - NIS Rheumatologie PI Oct. 2017
 - III Colitis ulcerosa Safety and efficiency of IMP during induction PI Since Dec. 2017
 - III Colitis ulcerosa Efficacy and safety of IMP compared with Infliximab PI Since Dec. 2017
 - III Mb Crohn Efficacy and safety of IMP as an induction and maintenance treatment PI Since 2017
 - NIS Colitis ulcerosa or Mb Crohn Non - interventional study to observe the safety and efficacy of IMP PI Since 2017
 - II Mb Crohn Controlled Study of IMP in subject with active crohn´s disease PI Since 2017
 - II Mb Crohn Efficacy, safety, and tolerability of treatment with IMP PI Since 2017
 - NIS Hepatocellular carcinoma Bayer REFINE - Observational study in hepatocellular carcinoma PI Jänner 2018- ongoing
 - III NASH Gilead STELLAR - Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis PI Jänner 2018-Feber 2018
 - NIS Hepatitis C Patients with Chronic Hepatitis C PI April 2018- ongoing
 - PASS ventricular arrhythmia Surveillance of Pharmacologic Therapy PI 2016-2018
 - III Hepatocellular Carcinoma COSMIC-312 RCT Cabozantinib + Atezolizumab vs. Sorafenib in advanced stage HCC PI 2019 - ongoing
 - III Hepatocellular Carcinoma IMbrave050 RCT Adjuvant Atezolizumab plus Bevacizumab vs. Placebo after curative resection/ablation for high-risk HCC PI 2020 - ongoing
 - III Hepatocellular Carcinoma BMS CA209-9DW RCT Nivolumab plus Ipilimumab vs. Sorafenib/Lenvatinib for advanced stage HCC July 2020 - ongoing
 - III NASH Madrigal -

- Memberships**
- Member of Professional societies:
- 1) European Association for the Study of the Liver (EASL)
 - 2) American Association for the Study of Liver Disease (AASLD)

- 3) International Association for the Study of the Liver (IASL)
- 4) Austrian Society of Gastroenterology and Hepatology (OEGGH)
- 5) Austrian Society of Internal Medicine (OEGIM)
- 6) Austrian Society for Infectious Diseases & Tropical Medicine (ÖGIT)

[Other Relevant Information](#)